The method also has the advantage of not requiring the patient to fast from food for several hours prior to a blood draw, enhancing the patient experience.
The development is the result of a license agreement between Quest Diagnostics and the Johns Hopkins University. The calculation is based on a formula from cardiologist Seth Martin, M.D., assistant professor of Medicine at the Johns Hopkins University School of Medicine.
It is designed to replace the Friedewald calculation, which has been the standard method used by laboratories for LDL-C analysis in cholesterol testing in the United States since 1972.
LDL-C blood assessment can also aid treatment decisions. National and international guidelines generally refer to a target level of
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy